0.01% Atropine Eye Drops in Children With Myopia and Intermittent Exotropia: The AMIXT Randomized Clinical Trial.

ABSTRACT:

Importance

Exotropia and myopia are commonly coexistent. However, evidence is limited regarding atropine interventions for myopia control in children with myopia and intermittent exotropia (IXT).

Objective

To evaluate the efficacy and safety of 0.01% atropine eye drops on myopia progression, exotropia conditions, and binocular vision in individuals with myopia and IXT.

Design, setting, and participants

This placebo-controlled, double-masked, randomized clinical trial was conducted from December 2020 to September 2023. Children aged 6 to 12 years with basic-type IXT and myopia of -0.50 to -6.00 diopters (D) after cycloplegic refraction in both eyes were enrolled.

Intervention

Participants were randomly assigned in a 2:1 ratio to 0.01% atropine or placebo eye dro

SUBMITTER: Wang Z 

PROVIDER: S-EPMC11223046 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature